Viewing Study NCT05780034

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:20 AM
Ignite Modification Date: 2026-02-06 @ 12:41 AM
Study NCT ID: NCT05780034
Status: RECRUITING
Last Update Posted: 2025-10-02
First Post: 2023-03-10
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Sponsor: Accutar Biotechnology Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed/Refractory B-cell Malignancies View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Chronic Lymphocytic Leukemia (CLL) View
None Small Lymphocytic Lymphoma (SLL) View
None Mantle Cell Lymphoma (MCL) View
None Follicular Lymphoma (FL) View
None Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma (DLBCL) View
None Marginal Zone Lymphoma (MZL View
None Waldenström Macroglobulinemia (WM) View
None Non-Hodgkin Lymphoma (NHL) View
None Bruton's tyrosine kinase-BTK View
None BTK Degrader View
None AC676 View
None AC0676 View